SCHEMBL13745761

SCHEMBL13745761

CN(C)c1ccc(-c2cnc3c(c2)c(I)cn3OOSc2ccccc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 1/20 0.37
▸ MAPK9 P45984 1/20 0.37
▸ MAPK10 P53779 1/20 0.37
▸ PDGFRB P09619 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ MAP4K1 Q92918 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ BRD4 O60885 1/20 0.32
▸ APP P05067 3/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ CASP1 P29466 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ RAF1 P04049 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13609303 0.85 ALDH1A1 (0.38) MAPK8MAPK9MAPK10PDGFRBPDGFRA
SCHEMBL13746285 0.83 KIT (0.34) MAPK8MAPK9MAPK10PDGFRBPDGFRA
SCHEMBL13609209 0.83 MAPK8 (0.32) MAPK8MAPK9MAPK10PDGFRBPDGFRA
SCHEMBL13745791 0.81 MAPK8 (0.31) MAPK8MAPK9MAPK10PDGFRBPDGFRA
SCHEMBL13745903 0.81 MAPK8 (0.37) MAPK8MAPK9MAPK10PDGFRBPDGFRA
SCHEMBL13609214 0.81 GRM5 (0.32) MAPK8MAPK9MAPK10GSK3B
SCHEMBL13609215 0.80 ADK (0.35) MAPK8MAPK9MAPK10GSK3BAPP
SCHEMBL14031108 0.78 DYRK1B (0.33) MAPK8CLK4AURKA
SCHEMBL13745928 0.77 CAMKK2 (0.41) BRD4MAOB
SCHEMBL13609216 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 — — US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 MAPK8 50/4885MAPK9 43/4885MAPK10 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback